Non-lamellar lyotropic liquid crystalline nanoparticles as nanocarriers for enhanced drug encapsulation of atorvastatin calcium and proanthocyanidins
Chem Phys Lipids. 2024 May;260:105377. doi: 10.1016/j.chemphyslip.2024.105377. Epub 2024 Feb 5.ABSTRACTAtorvastatin calcium (ATV) and proanthocyanidins (PAC) have a strong antioxidant activity, that can benefit to reduce the atherosclerotic plaque progression. Unfortunately, the bioavailability of ATV is greatly reduced due to its limited drug solubility while the PAC drug is unstable upon exposure to the atmospheric oxygen. Herein, the lyotropic liquid crystalline nanoparticles (LLCNPs) constructed by a binary mixture of soy phosphatidylcholine (SPC) and citric acid ester of monoglyceride (citrem) at different weight rati...
Source: Chemistry and Physics of Lipids - February 7, 2024 Category: Lipidology Authors: Mardhiah Maslizan Muhammad Salahuddin Haris Mokrish Ajat Siti Nurul Ain Md Jamil Shah Christirani Azhar N Idayu Zahid Intan Diana Mat Azmi Source Type: research
Non-lamellar lyotropic liquid crystalline nanoparticles as nanocarriers for enhanced drug encapsulation of atorvastatin calcium and proanthocyanidins
Chem Phys Lipids. 2024 May;260:105377. doi: 10.1016/j.chemphyslip.2024.105377. Epub 2024 Feb 5.ABSTRACTAtorvastatin calcium (ATV) and proanthocyanidins (PAC) have a strong antioxidant activity, that can benefit to reduce the atherosclerotic plaque progression. Unfortunately, the bioavailability of ATV is greatly reduced due to its limited drug solubility while the PAC drug is unstable upon exposure to the atmospheric oxygen. Herein, the lyotropic liquid crystalline nanoparticles (LLCNPs) constructed by a binary mixture of soy phosphatidylcholine (SPC) and citric acid ester of monoglyceride (citrem) at different weight rati...
Source: Chemistry and Physics of Lipids - February 7, 2024 Category: Lipidology Authors: Mardhiah Maslizan Muhammad Salahuddin Haris Mokrish Ajat Siti Nurul Ain Md Jamil Shah Christirani Azhar N Idayu Zahid Intan Diana Mat Azmi Source Type: research
Combination therapy of metformin and atorvastatin against benzopyrene-induced lung cancer via inflammatory signaling pathway
In this study, we scrutinized the chemoprotective effect of the metformin and atorvastatin combination against benzo[a]pyrene (BaP)-induced lung cancer in mice of Swiss albino. BaP (50 mg/kg) was used for induction of lung cancer and mice were treated with metformin, atorvastatin or their combination. Metformin + atorvastatin combination significantly (p< 0.001) improved the body weight, liver weight, suppressed the lung weight and tumor incidence and altered the levels of immunocompetent cells, polyamines, lung tumor markers, lung parameters and antioxidant parameters, respectively. Metformin + atorvastatin combination...
Source: General Physiology and Biophysics - February 5, 2024 Category: Physiology Authors: Xuecong Ning Shusen Zhang Zhiguo Gao Aimin Li Source Type: research
Combination therapy of metformin and atorvastatin against benzopyrene-induced lung cancer via inflammatory signaling pathway
In this study, we scrutinized the chemoprotective effect of the metformin and atorvastatin combination against benzo[a]pyrene (BaP)-induced lung cancer in mice of Swiss albino. BaP (50 mg/kg) was used for induction of lung cancer and mice were treated with metformin, atorvastatin or their combination. Metformin + atorvastatin combination significantly (p< 0.001) improved the body weight, liver weight, suppressed the lung weight and tumor incidence and altered the levels of immunocompetent cells, polyamines, lung tumor markers, lung parameters and antioxidant parameters, respectively. Metformin + atorvastatin combination...
Source: General Physiology and Biophysics - February 5, 2024 Category: Physiology Authors: Xuecong Ning Shusen Zhang Zhiguo Gao Aimin Li Source Type: research
Combination therapy of metformin and atorvastatin against benzopyrene-induced lung cancer via inflammatory signaling pathway
In this study, we scrutinized the chemoprotective effect of the metformin and atorvastatin combination against benzo[a]pyrene (BaP)-induced lung cancer in mice of Swiss albino. BaP (50 mg/kg) was used for induction of lung cancer and mice were treated with metformin, atorvastatin or their combination. Metformin + atorvastatin combination significantly (p< 0.001) improved the body weight, liver weight, suppressed the lung weight and tumor incidence and altered the levels of immunocompetent cells, polyamines, lung tumor markers, lung parameters and antioxidant parameters, respectively. Metformin + atorvastatin combination...
Source: General Physiology and Biophysics - February 5, 2024 Category: Physiology Authors: Xuecong Ning Shusen Zhang Zhiguo Gao Aimin Li Source Type: research
Combination therapy of metformin and atorvastatin against benzopyrene-induced lung cancer via inflammatory signaling pathway
In this study, we scrutinized the chemoprotective effect of the metformin and atorvastatin combination against benzo[a]pyrene (BaP)-induced lung cancer in mice of Swiss albino. BaP (50 mg/kg) was used for induction of lung cancer and mice were treated with metformin, atorvastatin or their combination. Metformin + atorvastatin combination significantly (p< 0.001) improved the body weight, liver weight, suppressed the lung weight and tumor incidence and altered the levels of immunocompetent cells, polyamines, lung tumor markers, lung parameters and antioxidant parameters, respectively. Metformin + atorvastatin combination...
Source: General Physiology and Biophysics - February 5, 2024 Category: Physiology Authors: Xuecong Ning Shusen Zhang Zhiguo Gao Aimin Li Source Type: research
Combination therapy of metformin and atorvastatin against benzopyrene-induced lung cancer via inflammatory signaling pathway
In this study, we scrutinized the chemoprotective effect of the metformin and atorvastatin combination against benzo[a]pyrene (BaP)-induced lung cancer in mice of Swiss albino. BaP (50 mg/kg) was used for induction of lung cancer and mice were treated with metformin, atorvastatin or their combination. Metformin + atorvastatin combination significantly (p< 0.001) improved the body weight, liver weight, suppressed the lung weight and tumor incidence and altered the levels of immunocompetent cells, polyamines, lung tumor markers, lung parameters and antioxidant parameters, respectively. Metformin + atorvastatin combination...
Source: General Physiology and Biophysics - February 5, 2024 Category: Physiology Authors: Xuecong Ning Shusen Zhang Zhiguo Gao Aimin Li Source Type: research
Combination therapy of metformin and atorvastatin against benzopyrene-induced lung cancer via inflammatory signaling pathway
In this study, we scrutinized the chemoprotective effect of the metformin and atorvastatin combination against benzo[a]pyrene (BaP)-induced lung cancer in mice of Swiss albino. BaP (50 mg/kg) was used for induction of lung cancer and mice were treated with metformin, atorvastatin or their combination. Metformin + atorvastatin combination significantly (p< 0.001) improved the body weight, liver weight, suppressed the lung weight and tumor incidence and altered the levels of immunocompetent cells, polyamines, lung tumor markers, lung parameters and antioxidant parameters, respectively. Metformin + atorvastatin combination...
Source: General Physiology and Biophysics - February 5, 2024 Category: Physiology Authors: Xuecong Ning Shusen Zhang Zhiguo Gao Aimin Li Source Type: research
Appropriateness of Intensive Statin Treatment in People with Type Two Diabetes and Mild Hypercholesterolemia: A Randomized Clinical Trial
CONCLUSION: Despite the general conception, moderate-intensity statins are not adequate for the majority of patients with T2DM and mild hyperlipidemia and greater numbers of patients could reach the LDL cholesterol target with high-intensity statin therapy.PMID:38310429 | PMC:PMC10685836 | DOI:10.34172/aim.2023.45 (Source: Archives of Iranian Medicine)
Source: Archives of Iranian Medicine - February 4, 2024 Category: Middle East Health Authors: Mohammad Taghi Gorji Fariba Alaei-Shahmiri Gisoo Darban Hosseini Amirkhiz Seyed Hashem Sezavar Mojtaba Malek Mohammad E Khamseh Source Type: research
Appropriateness of Intensive Statin Treatment in People with Type Two Diabetes and Mild Hypercholesterolemia: A Randomized Clinical Trial
CONCLUSION: Despite the general conception, moderate-intensity statins are not adequate for the majority of patients with T2DM and mild hyperlipidemia and greater numbers of patients could reach the LDL cholesterol target with high-intensity statin therapy.PMID:38310429 | PMC:PMC10685836 | DOI:10.34172/aim.2023.45 (Source: Archives of Iranian Medicine)
Source: Archives of Iranian Medicine - February 4, 2024 Category: Middle East Health Authors: Mohammad Taghi Gorji Fariba Alaei-Shahmiri Gisoo Darban Hosseini Amirkhiz Seyed Hashem Sezavar Mojtaba Malek Mohammad E Khamseh Source Type: research
Appropriateness of Intensive Statin Treatment in People with Type Two Diabetes and Mild Hypercholesterolemia: A Randomized Clinical Trial
CONCLUSION: Despite the general conception, moderate-intensity statins are not adequate for the majority of patients with T2DM and mild hyperlipidemia and greater numbers of patients could reach the LDL cholesterol target with high-intensity statin therapy.PMID:38310429 | PMC:PMC10685836 | DOI:10.34172/aim.2023.45 (Source: Archives of Iranian Medicine)
Source: Archives of Iranian Medicine - February 4, 2024 Category: Middle East Health Authors: Mohammad Taghi Gorji Fariba Alaei-Shahmiri Gisoo Darban Hosseini Amirkhiz Seyed Hashem Sezavar Mojtaba Malek Mohammad E Khamseh Source Type: research
Appropriateness of Intensive Statin Treatment in People with Type Two Diabetes and Mild Hypercholesterolemia: A Randomized Clinical Trial
CONCLUSION: Despite the general conception, moderate-intensity statins are not adequate for the majority of patients with T2DM and mild hyperlipidemia and greater numbers of patients could reach the LDL cholesterol target with high-intensity statin therapy.PMID:38310429 | PMC:PMC10685836 | DOI:10.34172/aim.2023.45 (Source: Archives of Iranian Medicine)
Source: Archives of Iranian Medicine - February 4, 2024 Category: Middle East Health Authors: Mohammad Taghi Gorji Fariba Alaei-Shahmiri Gisoo Darban Hosseini Amirkhiz Seyed Hashem Sezavar Mojtaba Malek Mohammad E Khamseh Source Type: research
Appropriateness of Intensive Statin Treatment in People with Type Two Diabetes and Mild Hypercholesterolemia: A Randomized Clinical Trial
CONCLUSION: Despite the general conception, moderate-intensity statins are not adequate for the majority of patients with T2DM and mild hyperlipidemia and greater numbers of patients could reach the LDL cholesterol target with high-intensity statin therapy.PMID:38310429 | PMC:PMC10685836 | DOI:10.34172/aim.2023.45 (Source: Archives of Iranian Medicine)
Source: Archives of Iranian Medicine - February 4, 2024 Category: Middle East Health Authors: Mohammad Taghi Gorji Fariba Alaei-Shahmiri Gisoo Darban Hosseini Amirkhiz Seyed Hashem Sezavar Mojtaba Malek Mohammad E Khamseh Source Type: research
Appropriateness of Intensive Statin Treatment in People with Type Two Diabetes and Mild Hypercholesterolemia: A Randomized Clinical Trial
CONCLUSION: Despite the general conception, moderate-intensity statins are not adequate for the majority of patients with T2DM and mild hyperlipidemia and greater numbers of patients could reach the LDL cholesterol target with high-intensity statin therapy.PMID:38310429 | PMC:PMC10685836 | DOI:10.34172/aim.2023.45 (Source: Archives of Iranian Medicine)
Source: Archives of Iranian Medicine - February 4, 2024 Category: Middle East Health Authors: Mohammad Taghi Gorji Fariba Alaei-Shahmiri Gisoo Darban Hosseini Amirkhiz Seyed Hashem Sezavar Mojtaba Malek Mohammad E Khamseh Source Type: research
Appropriateness of Intensive Statin Treatment in People with Type Two Diabetes and Mild Hypercholesterolemia: A Randomized Clinical Trial
CONCLUSION: Despite the general conception, moderate-intensity statins are not adequate for the majority of patients with T2DM and mild hyperlipidemia and greater numbers of patients could reach the LDL cholesterol target with high-intensity statin therapy.PMID:38310429 | PMC:PMC10685836 | DOI:10.34172/aim.2023.45 (Source: Archives of Iranian Medicine)
Source: Archives of Iranian Medicine - February 4, 2024 Category: Middle East Health Authors: Mohammad Taghi Gorji Fariba Alaei-Shahmiri Gisoo Darban Hosseini Amirkhiz Seyed Hashem Sezavar Mojtaba Malek Mohammad E Khamseh Source Type: research
